Published trials of donor-derived multivirus-specific T cells
| Virus . | Patient no. . | VST activator . | GVHD . | Antiviral effects . | Reference . |
|---|---|---|---|---|---|
| CMV, EBV, and ADV | 26 | Monocytes and LCLs transduced with ADV vector encoding CMV-pp65 | Two patients developed skin rashes that responded to topical steroids | Six out of 6 with EBV cleared infection; 5/6 with ADV cleared infection; 10/11 with CMV cleared infection; and 1 patient progressed despite VSTs/pharmacotherapy | 24, 61 |
| EBV and ADV | 14 | Monocytes and LCLs transduced with ADV vector | Three patients with skin rashes who responded to topical steroids | Eleven patients treated as prophylaxis remain negative; and 2/3 patients with ADV cleared the infection | 62 |
| CMV and ADV | 40 | ADV vector encoding CMV-pp65 | Grade 2-4 aGVHD in 24% of the CTL cohort and 18% of the controls | Fewer CMV reactivations than controls and only 1 patient required CMV-specific pharmacotherapy; immune reconstitution to CMV in CTL recipients | 26, 58 |
| 58 | |||||
| CMV and EBV | 3 | DCs pulsed with EBV-LMP2, CMV-pp65, and CMV-IE peptides | One patient with grade 1 | Treatment: cleared in 2/2; prophylaxis: no infections in 1 patient | 63 |
| CMV, EBV, and ADV | 10 | DCs nucleofected with viral antigens | One patient with skin rash due to GVHD or BK infection | Complete virologic responses in 8/10 patients | 25 |
| CMV, EBV, ADV, BK, and HHV6 | 11 | Pepmixes from immunodominant antigens | One patient with stage 2 skin GVHD (grade 1 overall) | Three patients treated as prophylaxis remained negative; and 8 patients with 18 viral infections/reactivations had a 94% response rate (15 complete and 2 PR) | 28 |
| CMV, EBV, ADV, and VZV | 10 | Ad5f35 encoding CMV-pp65, selected EBNA-1, and LMP EBV epitopes; commercial VZV vaccine | Three patients developed grade 2-4 GVHD | Ten patients treated as prophylaxis with no EBV, ADV, or VZV infections, and 1 with CMV infection | 59 |
| CMV, EBV, and ADV | 3 | Monocytes and LCLs transduced with ADV vector encoding CMV-pp65 | None | Treatment: cleared in 1/1; prophylaxis: no infections in 2 patients | 60 |
| CMV, EBV, and ADV | 6* | Pepmixes from immunodominant antigens | One patient with grade 1 and 1 with grade 2 GVHD | Two patients with EBV attained CR; 5 had CMV with 2 CRs; 2 with PR; and 1 failure | 64 |
| Virus . | Patient no. . | VST activator . | GVHD . | Antiviral effects . | Reference . |
|---|---|---|---|---|---|
| CMV, EBV, and ADV | 26 | Monocytes and LCLs transduced with ADV vector encoding CMV-pp65 | Two patients developed skin rashes that responded to topical steroids | Six out of 6 with EBV cleared infection; 5/6 with ADV cleared infection; 10/11 with CMV cleared infection; and 1 patient progressed despite VSTs/pharmacotherapy | 24, 61 |
| EBV and ADV | 14 | Monocytes and LCLs transduced with ADV vector | Three patients with skin rashes who responded to topical steroids | Eleven patients treated as prophylaxis remain negative; and 2/3 patients with ADV cleared the infection | 62 |
| CMV and ADV | 40 | ADV vector encoding CMV-pp65 | Grade 2-4 aGVHD in 24% of the CTL cohort and 18% of the controls | Fewer CMV reactivations than controls and only 1 patient required CMV-specific pharmacotherapy; immune reconstitution to CMV in CTL recipients | 26, 58 |
| 58 | |||||
| CMV and EBV | 3 | DCs pulsed with EBV-LMP2, CMV-pp65, and CMV-IE peptides | One patient with grade 1 | Treatment: cleared in 2/2; prophylaxis: no infections in 1 patient | 63 |
| CMV, EBV, and ADV | 10 | DCs nucleofected with viral antigens | One patient with skin rash due to GVHD or BK infection | Complete virologic responses in 8/10 patients | 25 |
| CMV, EBV, ADV, BK, and HHV6 | 11 | Pepmixes from immunodominant antigens | One patient with stage 2 skin GVHD (grade 1 overall) | Three patients treated as prophylaxis remained negative; and 8 patients with 18 viral infections/reactivations had a 94% response rate (15 complete and 2 PR) | 28 |
| CMV, EBV, ADV, and VZV | 10 | Ad5f35 encoding CMV-pp65, selected EBNA-1, and LMP EBV epitopes; commercial VZV vaccine | Three patients developed grade 2-4 GVHD | Ten patients treated as prophylaxis with no EBV, ADV, or VZV infections, and 1 with CMV infection | 59 |
| CMV, EBV, and ADV | 3 | Monocytes and LCLs transduced with ADV vector encoding CMV-pp65 | None | Treatment: cleared in 1/1; prophylaxis: no infections in 2 patients | 60 |
| CMV, EBV, and ADV | 6* | Pepmixes from immunodominant antigens | One patient with grade 1 and 1 with grade 2 GVHD | Two patients with EBV attained CR; 5 had CMV with 2 CRs; 2 with PR; and 1 failure | 64 |
aGVHD, acute GVHD; CMV-IE, CMV immediate-early; VZV, varicella-zoster virus.
Only included patients from this review that were not published elsewhere.